marked.bio

VEGFR2 TKI · small molecule

apatinib

9 active trials across 8 of our biomarkers, targeting VEGFR2. Not approved for any biomarker on marked.bio yet.

Also known as rivoceranib, YN968D1.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 5 5 Phase 3
BRCA1/2 mutation 2 4 Phase 3
MSI-H / dMMR 2 5 Phase 2
ALK fusion 0 2 –
EGFR exon 19 deletion / L858R 0 4 –
KRAS G12C 0 1 –
KRAS G12D 0 1 –
RET fusion or mutation 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of apatinib.

  1. LaNova Medicines Zhejiang 2
  2. AstraZeneca 1
  3. CARsgen Therapeutics 1

Trials

9 of 21 trials shown

  1. Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

    Active, not recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Started 2024Primary completion 2031-03 NCT07371910

    Chemotherapy/ADC RegimenFluorizoparibapatinibPhysician's Choice Chemotherapy/ADC Regimen

    Documented HRD-positive status (defined as BRCA1/2 mutation and/or HRD positive).

    BRCA1/2 mutationMetastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer

  2. Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

    Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Started 2024Primary completion 2031-03 NCT06255392

    fluzoparibapatinibcapecitabinevinorelbineeribulingemcitabinepaclitaxel

    3) The patient's HRD test was positive (definition: BRCA1/2 mutation, or HRD score greater than or equal to 42 points)

    BRCA1/2 mutationFludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer

  3. LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

    Active, not recruiting Phase 3 LaNova Medicines Zhejiang Started 2024Primary completion 2026-11 NCT06351020

    LM-302apatinibirinotecan

    Centrally confirmed CLDN18.2-positive

    Claudin 18.2 expressionLocally Advanced or Metastatic GC and GCJ Adenocarcinoma

  4. AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    Active, not recruiting Phase 3 AstraZeneca Started 2024Primary completion 2026-05 NCT06346392

    AZD0901ramucirumabpaclitaxeldocetaxelirinotecantrifluridine/tipiracilapatinib

    (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy.

    Claudin 18.2 expressionGastric Cancer, Gastroesophageal Junction Cancer

  5. Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

    Not yet recruiting Phase 2 China Medical University Started 2025Primary completion 2029-08 NCT06881017

    trastuzumabadebrelimabapatinibS-1capecitabineoxaliplatinzolbetuximab FDA EUtrastuzumab rezetecanSHR-A1904SHR-1701

    Archival or fresh tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1 expression);

    Claudin 18.2 expressionGastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive

  6. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

    Recruiting Phase 2 LaNova Medicines Zhejiang Started 2023Primary completion 2031-08 NCT05934331

    LM-302toripalimabcapecitabineTegafur, Gimeracil and Oteracil Potassium Capsulesnivolumabapatinibgemcitabinetislelizumabanlotinibbenmelstobart

    CLDN18.2-positive subjects.

    Claudin 18.2 expressionMalignant Neoplasms of Digestive Organs

  7. PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

    Recruiting Phase 2 Peking University Third Hospital Started 2023Primary completion 2026-04 NCT06792162

    apatinib

    Histologically confirmed unresectable stage III and IV dMMR (complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6), gastric adenocarcino…

    MSI-H / dMMRGastric Cancer

  8. KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

    Active, not recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2023Primary completion 2026-12 NCT06099821

    KN046regorafenibapatinib

    dMMR/MSI-H cancers resistant to PD1/PDL1 blockade.

    MSI-H / dMMRDigestive System Cancers

  9. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

    Active, not recruiting Phase 1/2 CARsgen Therapeutics Started 2020Primary completion 2024-10 NCT04581473

    satricabtagene autoleucelpaclitaxelirinotecanapatinib

    Phase Ib：Tumor tissue samples were positive for CLDN18.2 IHC staining； Phase II：Tumor tissue samples were positive for CLDN18.2 IHC staining and H…

    Claudin 18.2 expressionGastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma